Medigen Vaccine Biologics Total Liabilities
Medigen Vaccine Biologics total liabilities. Based on the latest financial reports, Medigen Vaccine Biologics (6547) has total liabilities worth NT$1.21 Billion TWD (≈ $37.98 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Medigen Vaccine Biologics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Medigen Vaccine Biologics (2012–2025)
Total liabilities of Medigen Vaccine Biologics from 2012 to 2025. This chart illustrates how Medigen Vaccine Biologics's total liabilities have evolved over time, based on quarterly financial data.
Medigen Vaccine Biologics Competitors by Total Liabilities
The table below lists competitors of Medigen Vaccine Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Community Healthcare Trust Inc
NYSE:CHCT
|
USA | $589.35 Million |
|
Salmones Camanchaca S.A
SN:SALMOCAM
|
Chile | CL$234.84 Million |
|
Jinxiandai Information Industry Co
SHE:300830
|
China | CN¥106.74 Million |
|
Keck Seng Malaysia Bhd
KLSE:3476
|
Malaysia | RM355.23 Million |
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
Brazil | R$13.36 Billion |
|
Caleres Inc
NYSE:CAL
|
USA | $1.45 Billion |
|
High Liner Foods Incorporated
TO:HLF
|
Canada | CA$583.12 Million |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
China | CN¥2.78 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Medigen Vaccine Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6547 total assets.
Liquidity & Leverage Metrics
Medigen Vaccine Biologics Total Liabilities Ratios Explained
Medigen Vaccine Biologics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medigen Vaccine Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medigen Vaccine Biologics (2012–2025)
The table below shows the annual total liabilities of Medigen Vaccine Biologics from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$454.64 Million ≈ $14.32 Million |
-11.53% |
| 2024-12-31 | NT$513.92 Million ≈ $16.19 Million |
-77.12% |
| 2023-12-31 | NT$2.25 Billion ≈ $70.76 Million |
-3.13% |
| 2022-12-31 | NT$2.32 Billion ≈ $73.05 Million |
+272.21% |
| 2021-12-31 | NT$622.95 Million ≈ $19.63 Million |
+78.29% |
| 2020-12-31 | NT$349.40 Million ≈ $11.01 Million |
-61.62% |
| 2019-12-31 | NT$910.28 Million ≈ $28.68 Million |
+59.39% |
| 2018-12-31 | NT$571.10 Million ≈ $17.99 Million |
-7.20% |
| 2017-12-31 | NT$615.41 Million ≈ $19.39 Million |
+76.89% |
| 2016-12-31 | NT$347.90 Million ≈ $10.96 Million |
+12.52% |
| 2015-12-31 | NT$309.19 Million ≈ $9.74 Million |
+127.43% |
| 2014-12-31 | NT$135.95 Million ≈ $4.28 Million |
+598.49% |
| 2013-12-31 | NT$19.46 Million ≈ $613.19K |
-12.13% |
| 2012-12-31 | NT$22.15 Million ≈ $697.85K |
-- |
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more